Neurovations

Industry
Healthcare Innovation
Founded Year
1992
Headquarters
Napa, California, United States
Employee Count
51

Key People

  • Dr. Eric Grigsby - CEO & Founder
  • Krista Clark - Director of Strategic Marketing
  • Pesc Valerie Stancliff - Project Manager
  • Danielle - Facilities Manager, CSPDT
  • Camille Grigsby-Rocca - Manager, Design and Innovation

Assessment

Team
Aspect: Multiple successful MedTech entrepreneurs
Summary: Led by Dr. Eric Grigsby, a seasoned physician innovator with extensive experience in medical device and pharmaceutical innovation.

Dr. Grigsby's leadership and the team's collective experience in MedTech innovation position Neurovations strongly in the healthcare sector.

Clinical Need
Aspect: Very Strong
Summary: Focuses on pain and neuroscience, addressing significant unmet needs in chronic pain management and neurological disorders.

The company's dedication to advancing treatments in pain and neuroscience aligns with critical healthcare demands, indicating a strong clinical need.

Competition
Aspect: Somewhat crowded
Summary: Operates in a competitive landscape with several established players in pain management and neuroscience.

While the market is competitive, Neurovations' innovative approach and clinical research focus may provide a competitive edge.

Technical Challenge
Aspect: Moderate
Summary: Developing and implementing new medical devices and therapies in pain and neuroscience presents moderate technical challenges.

The technical challenges are manageable with the company's expertise, though they require careful navigation to ensure successful outcomes.

Patent
Aspect: Mixed
Summary: The company's patent portfolio includes a combination of granted patents and pending applications.

A mixed patent portfolio suggests some level of intellectual property protection, but there may be areas requiring further strengthening.

Financing
Aspect: Medium
Summary: Secured funding from the National Institutes of Health, indicating moderate financial backing.

While NIH funding is a positive indicator, additional financing may be necessary to support expansive growth and development initiatives.

Regulatory
Aspect: Pivotal Trial
Summary: Engaged in pivotal trials, such as the RELIEV-CM2 study for chronic migraine therapy.

Participation in pivotal trials is crucial for regulatory approval, though it involves inherent risks and uncertainties.

Opportunity Rollup

Odds of Success
3.8
Peak Market Share
5.05
Segment CAGR
4.9%
Market Segment
Neurology Devices
Market Sub Segment
Pain Management Devices
Year Post Launch Market Penetration (%)
1 0.25
2 0.76
3 1.77
4 3.53
5 5.05

Key Takeaway

Neurovations, under the leadership of Dr. Eric Grigsby, is well-positioned in the growing pain management market, though it faces moderate competition and technical challenges.